Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Lexaria Bioscience Corp. LEXX
$0.75
-$0.03 (-3.88%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4729262.00000000
-
week52high
3.60
-
week52low
0.71
-
Revenue
255397
-
P/E TTM
-1
-
Beta
1.09065700
-
EPS
-1.16000000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 июл 2023 г. в 20:00
Описание компании
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Downey Gregory | A | 1954 | 121 | 14 окт 2022 г. |
| BUNKA CHRISTOPHER | A | 254412 | 16600 | 13 окт 2022 г. |
| McKechnie William Edward | A | 30000 | 18200 | 12 окт 2022 г. |
| REESE ALBERT L JR | A | 10000 | 3200 | 12 окт 2022 г. |
| TURKEL CATHERINE C. | A | 5000 | 1600 | 12 окт 2022 г. |
| BUNKA CHRISTOPHER | A | 237812 | 21900 | 12 окт 2022 г. |
| Baxter Nicholas W | A | 30000 | 18200 | 12 окт 2022 г. |
| TURKEL CATHERINE C. | A | 3400 | 3400 | 02 сент 2022 г. |
| Carle Vanessa | A | 40067 | 12500 | 29 авг 2022 г. |
| DOCHERTY JOHN MARTIN | A | 94668 | 30000 | 29 авг 2022 г. |
Новостная лента
9 Cannabis Stocks on Fire This Week
Schaeffers Research
29 июл 2022 г. в 15:45
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Why Shares Of Lexaria Biosciences Are Trading Higher
Benzinga
21 июн 2022 г. в 12:33
Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology. The first agreement is a manufacturing operating agreement that expands production capabilities for Lexaria's own growing list of business-to-.
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs
Benzinga
21 апр 2022 г. в 10:45
Lexaria Bioscience Corp (NASDAQ: LEXX) is receiving its first-ever patent for DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for Compositions and Methods.
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
InvestorPlace
14 апр 2022 г. в 15:22
Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares. The post Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Why Lexaria Shares Are Rising Today
Benzinga
14 апр 2022 г. в 10:47
Lexaria Bioscience Corp (NASDAQ: LEXX) said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-processed cannabidiol (DehydraTECH-CBD). The study findings indicated a tendency (p=0.1).